Gb Sciences will begin a dosing study for a cannabinoid-containing drug for the treatment of Parkinson’s disease
GB Sciences, Inc. GBLX chose the University of Lethbridge in Canada to carry out a dose range study patented formulations from Gb Sciences in a rodent model of Parkinson’s disease. The company plans to file a Iinvestigative notuh Drug aapplication start first in man clinical trials next year. As the second most common neurodegenerative disease, the Parkinson’s disease treatment market is expected to reach $8.8 billion by 2026.
Gb Sciences received US Patent No. 10,653,640 in May 2020 for its exclusive ownership therapeutic mixtures containing cannabinoids for the treatment of Parkinson’s disease. Animal studies conducted by the National Research Council of Canada found that Gb Sciences PD formulations achieved statistically significant reductions in PD-like motor symptoms associated with the loss of dopamine-producing neurons. Initial toxicity studies for these original PD formulas came back with no significant evidence of adverse effects.
By GbS Global Biopharma, its wholly-owned Canadian subsidiary, Gb Sciences, has signed a contract with the University of Lethbridge, located in Alberta, Canada, to carry out the required dose-response studies in rodents. These important studies will determine the range of doses of active ingredients that will be used in human trials and identify potential side effects. These dose-range studies are expected to begin next month.
“Our drug discovery process identified ratio-specific cannabinoid mixtures that provided a statistically significant reduction in Parkinsonian movement symptoms in an animal model; thus establishing our proof of concept for this therapeutic program,” said Dr. Andrea Small-Howard, president and scientific director of Gb Sciences. “Now, in collaboration with the University of Lethbridge, we are taking a big step forward in testing these cannabinoid ratio-specific formulations to establish the dose range for our first-in-human clinical trial.”
Essential minimum mixes
To create Gb Sciences’ new therapies, the company’s goal is to identify “minimum essential blends” that retain the efficacy of whole plant extracts, but with the advantages of manufacturing and product quality control. single ingredient pharmaceuticals. Gb Sciences uses its novel Pharos (Phytomedical Analytics for Research Optimization at Scale) predictive capabilities of the drug discovery engine, combined with rigorous high-throughput screening of potential combinations of these plant-derived compounds in established cellular models of disease to determine what minimum essential mixtures of these herbal materials can be therapeutically beneficial. These minimum essential mixtures are then validated and refined in animal models, in preparation for the first human trial.